| LivaNova to Present at the Jefferies Global Healthcare Conference |
LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on. |
businesswire.com |
2025-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript |
LivaNova PLC (NASDAQ:LIVN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Officer Ahmet Tezel – Chief Innovation Officer Alex Shvartsburg – Chief Financial Officer Stephanie Bolton – President, Global Epilepsy Conference Call Participants Rick Wise – Stifel David Roman – Goldman Sachs Adam Maeder – Piper Sandler Mike Sarcone – Jefferies Mike Matson – Needham & Co. David Rescott – Baird Michael Polark – Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC First Quarter 2025 Earnings Conference Call. My name is Emily, and I'll be coordinating your call today. |
seekingalpha.com |
2025-05-11 06:56:52 |
Czytaj oryginał (ang.) |
| LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates |
LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago. |
zacks.com |
2025-05-07 12:15:41 |
Czytaj oryginał (ang.) |
| LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance |
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period First-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA. |
businesswire.com |
2025-05-07 10:00:00 |
Czytaj oryginał (ang.) |
| LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy |
LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an A. |
businesswire.com |
2025-05-07 09:45:00 |
Czytaj oryginał (ang.) |
| LivaNova to Announce First-Quarter 2025 Results |
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time). |
businesswire.com |
2025-03-26 10:00:00 |
Czytaj oryginał (ang.) |
| LivaNova (LIVN) Tops Q4 Earnings Estimates |
LivaNova (LIVN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.87 per share a year ago. |
zacks.com |
2025-02-25 10:10:24 |
Czytaj oryginał (ang.) |
| LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance |
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. |
businesswire.com |
2025-02-25 08:00:00 |
Czytaj oryginał (ang.) |
| LivaNova to Present at the Barclays Global Healthcare Conference |
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should. |
businesswire.com |
2025-02-21 11:00:00 |
Czytaj oryginał (ang.) |
| LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results |
LONDON--(BUSINESS WIRE)-- #LIVN--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to rec. |
businesswire.com |
2025-01-21 11:00:00 |
Czytaj oryginał (ang.) |
| 5 Beaten-Down MedTech Stocks Set to Rebound in 2025 |
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape. |
zacks.com |
2024-12-30 11:25:28 |
Czytaj oryginał (ang.) |
| RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression |
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. |
businesswire.com |
2024-12-18 10:30:00 |
Czytaj oryginał (ang.) |
| LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting |
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles. |
businesswire.com |
2024-12-05 11:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know |
The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-28 13:01:24 |
Czytaj oryginał (ang.) |
| LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint |
LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. |
zacks.com |
2024-11-18 10:45:23 |
Czytaj oryginał (ang.) |
| LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints |
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. |
businesswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock? |
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-11-07 15:00:57 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2% |
The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-07 13:00:47 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for November 7th |
KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024. |
zacks.com |
2024-11-07 13:00:39 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for November 7th |
MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024. |
zacks.com |
2024-11-07 08:31:12 |
Czytaj oryginał (ang.) |
| Best Value Stocks to Buy for November 7th |
JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024. |
zacks.com |
2024-11-07 07:40:36 |
Czytaj oryginał (ang.) |
| LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript |
LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today. |
seekingalpha.com |
2024-10-30 16:30:24 |
Czytaj oryginał (ang.) |
| LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates |
LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago. |
zacks.com |
2024-10-30 10:15:25 |
Czytaj oryginał (ang.) |
| LivaNova Reports Third-Quarter 2024 Results |
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. |
businesswire.com |
2024-10-30 08:00:00 |
Czytaj oryginał (ang.) |
| LivaNova: Economics Should Start Making Sustained Improvements |
LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth. |
seekingalpha.com |
2024-10-18 07:45:53 |
Czytaj oryginał (ang.) |
| LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts |
Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. |
benzinga.com |
2024-10-04 15:59:44 |
Czytaj oryginał (ang.) |
| LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript |
LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – Baird Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2024 Earnings Conference Call. My name is Emily, and I'll be moderating your call today. |
seekingalpha.com |
2024-07-31 17:57:09 |
Czytaj oryginał (ang.) |
| LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates |
LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago. |
zacks.com |
2024-07-31 12:10:37 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN |
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2024-07-26 16:19:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN |
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-07-25 00:57:00 |
Czytaj oryginał (ang.) |